This article is only available to Business Times subscribers Subscribers: LOG IN or REGISTER for complete digital access. Not a Subscriber? SUBSCRIBE for full access to our weekly newspaper, online edition and Book of Lists. Check the STATUS of your Subscription Account.
This article is only available to Business Times subscribers Subscribers: LOG IN or REGISTER for complete digital access. Not a Subscriber? SUBSCRIBE for full access to our weekly newspaper, online edition and Book of Lists. Check the STATUS of your Subscription Account.
MannKind Corp. reported a substantial rise in revenue and a shrinking net loss in the third quarter of 2021 on Nov. 9, despite news since the quarter ended that the U.S. Food and Drug Administration will not yet approve a hypertension treatment the company is developing with United Therapeutics. MannKind, a Westlake Village-based biotechnology company Read More →
Atara Biotherapeutics continued seeing losses in the third quarter of fiscal year 2021, but has enough cash on hand to remain solvent as it awaits news on its tab-cel therapy treatment in early 2022. Atara, a South San Francisco-based immunotherapy based company with major operations in Westlake Village, reported net losses of $84.7 million in Read More →
Sales increases across Amgen’s drug lineup drove increases in revenue and non-GAAP earnings at the Thousand Oaks biotech company during the third quarter, according to its Nov. 2 earnings release, but pandemic issues persist, and the company lowered its revenue guidance for the year. Amgen, one of the largest biotech companies in the world, reported Read More →
The CEO of the two Dignity Health hospitals in Ventura County, Darren Lee, has resigned, Dignity Health announced Oct. 28. Lee was the top executive at of St. John’s Regional Medical Center in Oxnard and St. John’s Hospital Camarillo. In a statement announcing his departure, a hospital spokesperson said on Oct. 28 that he had Read More →
Shares of Westlake Village-based MannKind Corp. dropped 18% on Oct. 18, after the U.S. Food and Drug Administration did not approve a hypertension treatment the company is developing with United Therapeutics. In a complete letter response, the FDA declined to approve a new drug application for Tyvasio DPI, a treatment being developed by MannKind and Read More →